Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Pharmacogenomics in Clinical Practice
This book provides a practically applicable guide to the applications of pharmogenomics across medicine. Background information is provided on the mechanisms associated with membrane transporters, drug-metabolizing enzymes and their importance in pharmagenomics. Detailed guidance is subsequently presented on how to apply these techniques in disciplines including cardiology, gastroenterology, oncology, transplantation surgery, infectious diseases, anesthesia and analgesia, neurology, psychiatry, primary care, and public health. Clear easy-to-follow instructions are given on how to use big data technologies and public health databases in day-to-day clinical practice. Pharmacogenomics in Clinical Practice concisely covers how pharmacogenomic technologies and techniques can be applied in daily medical practice. It is therefore an ideal up-to-date resource for any medical practitioner, trainee or researcher across all medical disciplines who want to better understand how to use these techniques.
Genetic Testing
Collectively, genetic diseases and common diseases with a genetic component pose a significant public health burden. With completion of the human genome sequence, scientists will now focus on understanding the clinical implications of the sequence information. Clinical genetic tests are becoming available at a rapid rate. Testing is regulated by the federal government and tests are beginning to be included in health insurance benefits packages. Issues surrounding genetic testing and non-discrimination addressed in this book include: What is health information and how is it currently used by health insurers and employers?; What is genetic information?; Is genetic information different from other health information?; What are the implications of having genetic information: for the individual undergoing testing? for his/her family? for society?; What evidence exists to suggest that discrimination is a problem?; Will the proposed legislation have been sufficient to protect "genetic information" and "genetic tests" that are of concern?; How does the proposed legislation compare with existing laws and regulations governing discrimination?
Research Activities
None
Conflict of Interest and Medical Innovation
Scientific advances such as the sequencing of the human genome have created great promise for improving human health by providing a greater understanding of disease biology and enabling the development of new drugs, diagnostics, and preventive services. However, the translation of research advances into clinical applications has so far been slower than anticipated. This is due in part to the complexity of the underlying biology as well as the cost and time it takes to develop a product. Pharmaceutical companies are adapting their business models to this new reality for product development by placing increasing emphasis on leveraging alliances, joint development efforts, early-phase research ...
Refining Processes for the Co-Development of Genome-Based Therapeutics and Companion Diagnostic Tests
Many drug developers have examined new strategies for creating efficiencies in their development processes, including the adoption of genomics-based approaches. Genomic data can identify new drug targets for both common and rare diseases, can predict which patients are likely to respond to a specific treatment, and has the potential to significantly reduce the cost of clinical trials by reducing the number of patients that must be enrolled in order to demonstrate safety and efficacy. A key component of the approval of targeted therapeutics is the ability to identify the population of patients who will benefit from treatment, and this has largely hinged on the co-development and co-submission...
Molecular Diagnostics
Advances in genomic and proteomic profiling of disease have transformed the field of molecular diagnostics, thus leading the way for a major revolution in clinical practice. While the range of tests for disease detection and staging is rapidly expanding, many physicians lack the knowledge required to determine which tests to order and how to interpret results. Molecular Diagnostics provides a complete guide to the use and interpretation of molecular testing in the clinical arena. No other available resource offers this emphasis, comprehensive scope, and practical utility in the clinical setting. Serves as the definitivereference for molecular pathologists worldwide Covers a variety of molecular techniques including next generation sequencing, tumor somatic cell genotyping, infectious and genetic disease tecting, and pharmacogenetics Discusses in the detail issues concerning quality assurance, regulation, ethics, and future directions for the science
Genetics Testing in the New Millennium
Hearing held by the Subcommittee on Technology. Witnesses include: Raymond G. Kammer, Director, National Institute of Standards and Technology; Dr. Francis S. Collins, Director, National Human Genome Research Institute, National Institutes of Health; Dr. William F. Raub, Deputy Assistant Secretary of Science Policy, Department of Health and Human Services (HHS); and Dr. Michael Watson, Professor of Pediatrics and Genetics, Washington University School of Medicine, Co-Chair, NIH-DoE Task Force of Genetics Testing.
